IS7398A - Lyfjablanda sem felur í sér N-((1-N-bútýl-4-píperídínýl)metýl)-3,4-díhýdró-2H-(1,3)oxasínó(3,2-A)indól-10-karboxamíð eða salt og aðferð þar að lútandi sem felur í sér þurrkornamyndun - Google Patents

Lyfjablanda sem felur í sér N-((1-N-bútýl-4-píperídínýl)metýl)-3,4-díhýdró-2H-(1,3)oxasínó(3,2-A)indól-10-karboxamíð eða salt og aðferð þar að lútandi sem felur í sér þurrkornamyndun

Info

Publication number
IS7398A
IS7398A IS7398A IS7398A IS7398A IS 7398 A IS7398 A IS 7398A IS 7398 A IS7398 A IS 7398A IS 7398 A IS7398 A IS 7398A IS 7398 A IS7398 A IS 7398A
Authority
IS
Iceland
Prior art keywords
pharmaceutical composition
salt
dry granulation
granules
weight
Prior art date
Application number
IS7398A
Other languages
English (en)
Other versions
IS2393B (is
Inventor
Chrisopher Buxton Philip
Elizabeth Groves Sharon
Thomson Seona
Marinus Johannes Van Schie Dirk
Trevor Yeates Kenneth
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0203526A external-priority patent/GB0203526D0/en
Priority claimed from GB0203528A external-priority patent/GB0203528D0/en
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of IS7398A publication Critical patent/IS7398A/is
Publication of IS2393B publication Critical patent/IS2393B/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
IS7398A 2002-02-14 2004-08-12 Lyfjablanda sem felur í sér N-((1-N-bútýl-4-píperídínýl)metýl)-3,4-díhýdró-2H-(1,3)oxasínó(3,2-A)indól-10-karboxamíð eða salt og aðferð þar að lútandi sem felur í sér þurrkornamyndun IS2393B (is)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0203526A GB0203526D0 (en) 2002-02-14 2002-02-14 Process and composition
GB0203528A GB0203528D0 (en) 2002-02-14 2002-02-14 Process and composition
PCT/GB2003/000217 WO2003068193A1 (en) 2002-02-14 2003-01-22 Pharmaceutical composition comprising n- ((1-n-butyl-4-piperidinyl) methyl)-3, 4-dihydro-2h- (1, 3) oxazino (3, 2-a) indole-10-carboxamide or salt and process therefor comprising dry granulation

Publications (2)

Publication Number Publication Date
IS7398A true IS7398A (is) 2004-08-12
IS2393B IS2393B (is) 2008-08-15

Family

ID=27736214

Family Applications (1)

Application Number Title Priority Date Filing Date
IS7398A IS2393B (is) 2002-02-14 2004-08-12 Lyfjablanda sem felur í sér N-((1-N-bútýl-4-píperídínýl)metýl)-3,4-díhýdró-2H-(1,3)oxasínó(3,2-A)indól-10-karboxamíð eða salt og aðferð þar að lútandi sem felur í sér þurrkornamyndun

Country Status (21)

Country Link
US (1) US20050075335A1 (is)
EP (1) EP1476136B1 (is)
JP (1) JP2005523276A (is)
KR (1) KR100967782B1 (is)
AT (1) ATE329581T1 (is)
AU (1) AU2003202058B2 (is)
BR (1) BR0307666A (is)
CA (1) CA2475659A1 (is)
CO (1) CO5611095A2 (is)
CY (1) CY1106148T1 (is)
DE (1) DE60306120T2 (is)
DK (1) DK1476136T3 (is)
ES (1) ES2263949T3 (is)
IS (1) IS2393B (is)
MX (1) MXPA04007857A (is)
NO (1) NO20043834L (is)
NZ (1) NZ534333A (is)
PL (1) PL206544B1 (is)
PT (1) PT1476136E (is)
RU (1) RU2329789C2 (is)
WO (1) WO2003068193A1 (is)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0211230D0 (en) * 2002-05-16 2002-06-26 Medinnova Sf Treatment of heart failure
CA2406592C (en) * 2002-10-04 2003-09-30 Duchesnay Inc. Method of preparing pharmaceutical dosage forms containing multiple active ingredients
PE20060373A1 (es) 2004-06-24 2006-04-29 Smithkline Beecham Corp Derivados 3-piperidinil-7-carboxamida-indazol como inhibidores de la actividad cinasa de ikk2
US8063071B2 (en) 2007-10-31 2011-11-22 GlaxoSmithKline, LLC Chemical compounds
CN101437492A (zh) * 2006-05-04 2009-05-20 诺瓦提斯公司 用于制备药物组合物的热滚压法
AR065804A1 (es) 2007-03-23 2009-07-01 Smithkline Beecham Corp Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento
SI2170292T1 (sl) * 2007-06-22 2014-05-30 Bristol-Myers Squibb Holdings Ireland Tabletirani sestavki, ki vsebujejo atazanavir
ES2686081T3 (es) * 2007-07-31 2018-10-16 Cargill, Incorporated Dextrosa comprimible directamente
EP2406249A1 (en) 2009-03-10 2012-01-18 Glaxo Group Limited Indole derivatives as ikk2 inhibitors
TW201129386A (en) * 2009-11-05 2011-09-01 Fmc Corp Microcrystalline cellulose and calcium phosphate compositions useful as pharmaceutical excipients
TWI461213B (zh) * 2009-11-05 2014-11-21 Fmc Corp 作為藥物賦形劑之微晶纖維素及磷酸鈣之組合物
RU2564922C2 (ru) * 2011-04-19 2015-10-10 Григорий Яковлевич ЛЕГИН Композиция для изготовления спороцидных композиций надуксусной кислоты, способ (варианты) и набор для его осуществления
US9606054B2 (en) 2013-09-30 2017-03-28 Advantest Corporation Methods, sampling device and apparatus for terahertz imaging and spectroscopy of coated beads, particles and/or microparticles
US9417181B2 (en) 2014-05-08 2016-08-16 Advantest Corporation Dynamic measurement of density using terahertz radiation with real-time thickness measurement for process control
WO2016126012A1 (en) * 2015-02-05 2016-08-11 Boryung Pharmaceutical Co., Ltd Tablet and method of preparing the same
KR101545268B1 (ko) 2015-02-05 2015-08-20 보령제약 주식회사 정제 및 이의 제조방법
CN104945303B (zh) * 2015-06-15 2017-09-29 浙江工业大学 3‑烯基吲哚类化合物的制备方法
KR20230005270A (ko) 2020-04-24 2023-01-09 아스트라제네카 아베 약학적 제형
KR102499289B1 (ko) * 2022-04-15 2023-02-14 주식회사 비에스앤코 가루치약의 제조방법

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3134719A (en) * 1962-04-05 1964-05-26 American Cyanamid Co Calcium phosphates in tablet compressing
US5066441A (en) * 1980-12-12 1991-11-19 Rhone-Poulenc Basic Chemicals Co. Process for compacting a calcium phosphate composition
US4597969A (en) * 1982-04-05 1986-07-01 Merck Sharp & Dohme Stabilization of unstable drugs or food supplements
US4713245A (en) * 1984-06-04 1987-12-15 Mitsui Toatsu Chemicals, Incorporated Granule containing physiologically-active substance, method for preparing same and use thereof
US5055307A (en) * 1988-12-29 1991-10-08 Asahi Kagaku Kogyo Kabushiki Kaisha Slow release drug delivery granules and process for production thereof
US5861172A (en) * 1991-05-08 1999-01-19 Laboratorios Beecham Sa Pharmaceutical formulations of compacted granulates of β-lactam antibiotics
US5852014A (en) * 1992-03-12 1998-12-22 Smithkline Beecham P.L.C. Condensed indole derivatives as 5HT4 -receptor antagonists
SG50693A1 (en) * 1992-03-12 1998-07-20 Smithkline Beecham Plc Pharmaceuticals
US5998409A (en) * 1992-03-12 1999-12-07 Smithkline Beecham Plc Condensed indole derivatives as 5HT4 -receptor antagonists
GB9408117D0 (en) * 1994-04-23 1994-06-15 Smithkline Beecham Corp Pharmaceutical formulations
DE4418837A1 (de) * 1994-05-30 1995-12-07 Bayer Ag Thermisches Granulierverfahren
FR2740357B1 (fr) * 1995-10-25 1997-11-28 Rhone Poulenc Chimie Granules redispersables dans l'eau comprenant une matiere active sous forme liquide et un tensio-actif non ionique du type alcoxyles
CN1104435C (zh) * 1996-08-16 2003-04-02 史密丝克莱恩比彻姆有限公司 N－[(1－正丁基－4－哌啶基)甲基]－3,4－二氢－2H－[1,3] 噁嗪并[3,2－α]吲哚－10－甲酰胺及其盐的制备方法及在本方法中的中间体的制备方法
JP2004505930A (ja) * 2000-08-07 2004-02-26 ラボラトワール・グラクソスミスクライン・ソシエテ・パール・アクシオン・シンプリフィエ 心房細動の予防または治療のための薬物の製造における５ｈｔ４受容体アンタゴニストの使用
AU2001276558B2 (en) * 2000-08-08 2005-11-24 Smithkline Beecham P.L.C. Pharmaceutical composition comprising condensed indole compound
NZ535261A (en) * 2000-08-08 2004-12-24 Smithkline Beecham P A tablet comprising the hydrochloride salt of N-(1-nbutyl-4-piperidinyl)methyl]-3,4-[1,3]oxazino[3,2-a] indole-10-carboxamide
US6666298B2 (en) * 2001-11-21 2003-12-23 John Volkman Hanging scaffold support

Also Published As

Publication number Publication date
ES2263949T3 (es) 2006-12-16
DK1476136T3 (da) 2006-10-09
CO5611095A2 (es) 2006-02-28
EP1476136A1 (en) 2004-11-17
RU2004127450A (ru) 2005-04-10
ATE329581T1 (de) 2006-07-15
JP2005523276A (ja) 2005-08-04
NZ534333A (en) 2006-05-26
EP1476136B1 (en) 2006-06-14
NO20043834L (no) 2004-10-26
CY1106148T1 (el) 2011-06-08
US20050075335A1 (en) 2005-04-07
RU2329789C2 (ru) 2008-07-27
AU2003202058A1 (en) 2003-09-04
BR0307666A (pt) 2005-01-11
AU2003202058B2 (en) 2009-05-28
DE60306120T2 (de) 2006-11-09
PT1476136E (pt) 2006-10-31
KR20040097996A (ko) 2004-11-18
PL371963A1 (en) 2005-07-11
HK1072359A1 (en) 2005-08-26
WO2003068193A1 (en) 2003-08-21
IS2393B (is) 2008-08-15
MXPA04007857A (es) 2004-10-15
DE60306120D1 (de) 2006-07-27
CA2475659A1 (en) 2003-08-21
PL206544B1 (pl) 2010-08-31
KR100967782B1 (ko) 2010-07-05

Similar Documents

Publication Publication Date Title
IS7398A (is) Lyfjablanda sem felur í sér N-((1-N-bútýl-4-píperídínýl)metýl)-3,4-díhýdró-2H-(1,3)oxasínó(3,2-A)indól-10-karboxamíð eða salt og aðferð þar að lútandi sem felur í sér þurrkornamyndun
CA2470601A1 (en) Co-processed carbohydrate system as a quick-dissolve matrix for solid dosage forms
CA2339991A1 (en) Microemulsions as solid dosage forms for oral administration
JO2560B1 (en) Tablets decompose in the mouth and the process of their preparation
HRP20100399T1 (hr) Oralno dezintegrirajući pripravak olanzapina ili donepezila
SA94150373A (ar) صياغات جديدة واستخدام صياغة في علاج و/أوالوقاية من اضطرابات معينة
CA2342634A1 (en) Pharmaceutical composition comprising entacapone or nitecapone as well as a cross-linked cellulose derivative
CA2469019A1 (en) Pharmaceutical composition comprising a 5ht1 receptor agonist
EA200600675A1 (ru) Гранулы, содержащие гидрохлорид венлафаксина
MXPA03008420A (es) Forma farmaceutica solida oralmente dispersa.
CA2353693A1 (en) Pharmaceutical composition containing citalopram
TW200509995A (en) Pharmaceutical composition as solid dosage form and method for manufacturing thereof
RU2013127273A (ru) ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, АДАПТИРОВАННАЯ ДЛЯ ОРАЛЬНОГО ВВЕДЕНИЯ, И СПОСОБ ЕЕ ПОЛУЧЕНИЯ ДЛЯ ПРЕДОТВРАЩЕНИЯ И ЛЕЧЕНИЯ СИНДРОМА РАЗДРАЖЕННОГО КИШЕЧНИКА НА ОСНОВЕ МОДИФИКАТОРА МОТОРИКИ КИШЕЧНИКА И ФЕРМЕНТА α-D-ГАЛАКТОЗИДАЗЫ
IL182549A0 (en) Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby
EA200801614A1 (ru) Фармацевтическая композиция, содержащая монтелукаст
TW200505504A (en) Saquinavir mesylate oral dosage form
CA2217238A1 (en) Cross-linked cellulose as a tablet excipient
EA200300768A1 (ru) Фармацевтическая композиция, содержащая циталопрам
WO2007010369B1 (en) Sustained release formulation of alprazolam
WO2005034919A3 (en) Method of producing dosage units of a solid drug form containing warfarin sodium salt as active component
WO2005034954A3 (en) Pharmaceutical compositions of paroxetine containing microcrystalline cellulose, prepared by wet granulation
EA200600932A1 (ru) Таблетки циталопрама гидробромида
HRP20040165A2 (en) Citalopram for the treatment of elevated blood pressure
WO2005063202A3 (en) Method for preparing solid dosage form of desmopressin
TW200503728A (en) Suspension pharmaceutical composition containing budesonide and method for producing the same